Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu

5 Tips from Venture Capitalists on Raising Capital for Your Biotech Startup

February 8, 2022/in News /by Jessica Hogan

Research and development are vital for any biotech startup, however, raising venture capital (VC) can be a challenge for even the most experienced entrepreneurs. During November’s 2021 Biotech Start-Up Symposium, we were happy to have several VCs, industry leaders and experienced attorneys join us to provide key insights on what startup pioneers should know before pitching to a VC firm.

Tip 1: Know Thy Investor

Start by creating a potential roster of VCs that have a history of investing in the biotech space that you are part of. Pitching to a VC firm without sector experience in the biological arena is risky. Chances are they don’t know the ins and outs of getting a drug or device to market – let alone the science behind your idea. According to Dr. Anique ter Braake of M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany “Institutional VC firms’ business is based on high risk high return promise of innovation in start-up companies. Strategic investors are not different, but more weight is put on strategic returns. With either mechanism, it is important to understand the field with all the risks and benefits that you will encounter along the way, which can be pretty lengthy in venture investing. Taking a biotech or tech startup from inception to  realization of their offering is not for the faint hearted.  These are long-term relationships – that many state akin to a marriage,” she said. Finding a VC firm that understands that concept is vitally important.

“These are long-term relationships – akin to a marriage.”

~Dr. Anique ter Braake, M Ventures

Tip 2: Put Yourself in the Shoes of the Investor

During the symposium, Matthew Meyer, Chief Business Advisor at the law firm Wilson Sonsini, said VC firms look at more than just your idea. He said, “Investors want to know why this opportunity? Why you? And why now?” Investors are more likely to trust their money with companies and individuals with deep domain expertise, a passion for solving problems and working in a big market.

Dr. ter Braake reminded attendees of the symposium that “as with many walks of life, you mostly will have only one chance to make a first impression.” So come up with a strong point plan and positioning strategy while also having a detailed plan for what your investor’s money will be used for if they choose to invest with you.

“Investors want to know why this opportunity? Why you? And why now?”

~Matthew Meyer, Wilson Sonsini

Tip 3: Don’t Oversell Your Idea

You love your idea and have spent countless hours making it a reality. But keep in mind that it’s easy to get caught up in the excitement and prospects of your own idea. Ms. ter Braake reminded attendees of the symposium that overselling your idea will set off alarm bells that you will not be able to un-ring.

She went on to say, “When VC firms hear statements like “We will see no side effects at all” or “There is no competition,” they are immediately skeptical. In most cases, VCs you meet have already done a quick analysis of the opportunity hence know more than what they may show at the meeting. Chances are that someone else has thought of something similar or another group of scientists are working to solve the problem in a different way. It’s important to be confident but stay factual. Investors want to know what is different about your idea, what problem it will solve, and why you are the best team to deliver that.

Tip 4: Communicate! Communicate! Communicate!

When looking outward for funding don’t forget to look inward at how your team is communicating with one another. Dr. Johnson reminded attendees that an effective intellectual property (IP) strategy means getting all team members on the same page. Ensure your entire team attends regularly scheduled meetings to discuss the latest developments and to make each department aware of what is going on elsewhere. Working in closed-off silos will lead to problems downstream. But regularly scheduled meetings between your R&D team, management, IP counsel and anyone else on your IP strategy team is key to VC success.

“An effective ongoing IP strategy should involve open communication.”

 ~Dr. Lee A. Johnson, Wilson Sonsini

Tip 5: Expect the Unexpected

You’ve done your research, scheduled a meeting with a potential investor and are about to pitch your idea. Suddenly, the electricity goes out in the conference room and the pitch deck you’ve spent so much time on can’t be shared on the big screen.

It sounds silly. But these things happen. Anyone who has attended a Zoom meeting recently knows that audio and visual issues are common. The best defense is to know your material cold. You and your team have to know your data like the back of your hand, so it can be shared no matter where you are or who you are with. Mr. Meyer said it best when he said “Remember that this is hard work. Try to embrace it.”

One Last Thing

Before finishing her session, Dr. ter Braake shared one last piece of advice for biotech pioneers: “Keep at it. Just because they said “no” the first time doesn’t mean they will the second or third time.”

“Keep at it. Just because they said “no” the first time

doesn’t mean they will the second or third time.”

~Dr. Anique ter Braake, M Ventures

 

  • Author
  • Recent Posts
Lee Johnson
Patents and Innovations Partner at Wilson Sonsini
Lee provides counsel and assistance to clients in intellectual property matters, including patent counseling, drafting, and prosecution. Lee also represents clients in IP disputes before the courts and before the U.S. Patent and Trademark Office (USPTO), and he regularly acts on behalf of both investors and growth-stage innovative companies and transactional IP counsel in licensing and technology transfer matters, research collaborations and partnerships, initial public offerings (IPOs), mergers, and acquisitions. Lee represents clients from a range of industries, including biotechnology, pharmaceuticals, medical devices, and agriculture and food technologies.
Latest posts by Lee Johnson (see all)
    • Author
    • Recent Posts
    Matthew Meyer
    Matthew Meyer
    Chief Client Corporate Development Advisor at Wilson Sonsini
    Matthew, is an experienced life science executive and corporate attorney who has held diverse roles across a wide range of private and public biopharma, MedTech, and precision medicine companies from start-ups to Fortune 50 in the U.S. and Europe. Matthew has led, structured and negotiated dozens of life science business development, joint venture and licensing transactions and has been instrumental in raising over $250 million for life science companies.
    Matthew Meyer
    Latest posts by Matthew Meyer (see all)
      0
      Share this entry
      • Share on Facebook
      • Share on Twitter
      • Share on LinkedIn
      • Share by Mail
      http://emergingbiotalk.com/wp-content/uploads/2022/01/shutterstock_1452103277_RocketMoney-1-scaled.jpg 1707 2560 Jessica Hogan http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Jessica Hogan2022-02-08 18:37:282022-02-08 18:37:285 Tips from Venture Capitalists on Raising Capital for Your Biotech Startup

      Biotech Resource Hub >>

      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020
      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020

      Tags

      applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

      Business Hours

      Our support Hotline is available 24 Hours a day: (555) 343 456 7891

      • Monday-Friday: 9am to 5pm
      • Saturday: 10am to 2pm
      • Sunday: Closed

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
      • The Future of BiopharmaDecember 6, 2022 - 4:39 am
      • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
      • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar
      • Author
      • Recent Posts
      Matthew Meyer
      Matthew Meyer
      Chief Client Corporate Development Advisor at Wilson Sonsini
      Matthew, is an experienced life science executive and corporate attorney who has held diverse roles across a wide range of private and public biopharma, MedTech, and precision medicine companies from start-ups to Fortune 50 in the U.S. and Europe. Matthew has led, structured and negotiated dozens of life science business development, joint venture and licensing transactions and has been instrumental in raising over $250 million for life science companies.
      Matthew Meyer
      Latest posts by Matthew Meyer (see all)
        0
        © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
        Recognizing and Rewarding Innovation Envisioning the Future of Analytical Development for Gene Therapies
        Scroll to top

        This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

        Accept All CookiesCookie Settings

        Cookie and Privacy Settings



        Cookie Preferences

        When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
        Privacy Statement

        Necessary

        Always Active
        These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

        Functional

        These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

        Targeting

        These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

        Confirm My ChoicesAllow AllDisable All

        loading

        Please wait while you are redirected to the right page...

        Please share your location to continue.

        Check our help guide for more info.

        share your location